Health systems’ slow financial recovery opens door for more PE deals, growth in micro-hospitals

Among not-for-profit health systems, the largest — defined as those with more than $20 billion in operating revenue — have had the thinnest operating margins in recent years, as the healthcare industry continues its gradual post-pandemic recovery.
This finding, from McKinsey & Co.’s annual report on U.S. healthcare economics, indicates that “scale alone does not guarantee stronger margins,” the authors noted.
McKinsey assigned approximately 195 not-for-profit health systems into four groups based on their average reported operating revenue for 2023, 2024, and 2025.
While the nine largest non-municipal health systems (those in the $20 billion-plus group) collectively saw their operating margins improve during the three-year period (from -1.4% in 2023 to 0.7% in 2025), their margins were considerably lower than those for the other three groups.
By comparison, the group reporting less than $5 billion in operating revenue (the lowest of the four groups) had a margin of 3.0% in 2025.
The comparator group of for-profit health systems reporting more than $20 billion in average operating revenue had a margin of 16.0% in 2025.
Overall, general acute hospital EBITDA margins increased from 6.9% in 2023 to 8.9% in 2025, according to the report. Though the expiration of ACA subsidies and federal policy changes could continue to suppress margins through 2027, the outlook is for margins to remain “broadly stable” through 2030.
When looking at provider EBITDA margins as a whole, McKinsey found that growth has been strongest in pre-acute settings, such as ambulatory surgery centers and urgent care clinics. Post-acute care segments, such as home health and hospice, have also seen substantial growth in EBITDA margins.
The “continued migration of care toward lower-cost, freestanding, and ambulatory sites of care” will likely decrease hospitals’ share of overall provider profits to about 39% by 2030, according to McKinsey.
A separate report from the Private Equity Stakeholder Project (PESP) provides an in-depth look at ownership of U.S. hospitals by private equity firms.
According to the October 2026 PESP Private Equity Hospital Tracker, PE firms owned or operated approximately 561 hospitals, a total that represents approximately 11.9% of the country’s 4,714 private (non-government) facilities and 33.6% of the country’s 1,668 proprietary for-profit hospitals.
PESP said a small number of PE firms own or operate the majority of the 561 hospitals, with Apollo Global Management at the top of the list. Apollo owns or operates at least 203 locations through its two health systems, Lifepoint Health and ScionHealth.
Welsh, Carson, Anderson & Stowe WCAS) is part of two investor consortiums that own Select Medical Holdings and Emerus Hospital Partners. Collectively, Select Medical and Emerus operate 124 hospitals. (See more on Emerus below.)
Of the PE-owned and -operated hospitals, 24.6% are rehabilitation facilities, 23.4% are non-specialty hospitals, 22.6% are long-term acute care hospitals, and 19.4% are psychiatric facilities.
Our Take: PE firms often try to make a sizable profit on their investment by selling the hospitals they acquire within a few years. In the interim, PESP noted, the PE firms may implement a number of tactics to make money on their investment. These include, but are not limited to, doing a leveraged buyout to make the acquisition and then diverting cash away from the hospital’s operations to pay interest on the debt; doing a sale-leaseback of the hospital’s real estate to monetize it and generate cash; charging the hospital exorbitant management or advisory fees; or siphoning money out of the hospital through dividend recapitalization.
These tactics generally leave the hospitals in a weaker financial position, with fewer assets and at risk for reorganization or bankruptcy. PESP pointed to Steward Health Care and Prospect Medical Holdings as two recent examples. These and other high-profile bankruptcies have trained a spotlight on the deleterious practices sometimes associated with PE ownership of hospitals.
Research has also demonstrated that PE ownership can lead to higher patient costs, poorer quality of care, and more adverse health outcomes — such as increased falls and hospital-acquired infections. PE firms and their lobbying organizations have pushed back against these findings, claiming their investments improve access to, and quality of, care.
Emerus Hospital Partners may be one of the more positive instances of PE involvement with hospitals. Emerus is the nation’s largest developer and operator of neighborhood hospitals, also called micro-hospitals.
The company partners with non-profit and regional health systems wanting to increase their presence in neighborhoods that are growing or underserved. Ascension, Baptist Health, Baylor Scott & White, ChristianaCare, and Wellspan are among the health systems that have partnered with Emerus “to test the micro-hospital model,” Healthcare Dive reported in an article featuring Mon Marion Neighborhood Hospital in White Hall, W.Va.
Dave Hall, Emerus’ chief growth officer, told Healthcare Dive that the company operates or owns 52 micro-hospitals and has another 24 in development. Hall said interest in the hospitals is growing, citing issues that are disrupting revenue streams for traditional health systems — cost pressures, labor shortages, reimbursement challenges, and policy upheaval — as reasons for the uptick in interest.
Micro-hospitals can be faster and up to 10 times less expensive to build, according to the article. They typically have an emergency department and 8 to 25 inpatient beds, and they can provide basic imaging and lab services, but they have no operating rooms or labor and delivery units. They normally do not have specialty physicians on staff, either, but virtual consultations can be conducted with specialists in nearby hospitals.
In most cases, low-acuity patients can get all the care they need at a micro-hospital for a fraction of what it would cost at a larger hospital. Higher-acuity patients can be stabilized before being transferred to a larger hospital if they require additional care.
While neighborhood hospitals like Mon Marion can be a close, cost-effective choice for patients in rural areas, where other options are few and literally far between, Hall said Emerus is also expanding in metro areas such as Dallas, with the goal of creating more competition for healthcare services.
We’ve seen the ongoing shift toward lower-cost ambulatory settings McKinsey describes in its report, with Ascension paying $3.9 billion to acquire AmSurg and Tenet continuing to add ASCs to the portfolio of its United Surgical Partners International subsidiary.
HCA Healthcare has invested heavily in ASCs, urgent care clinics, and freestanding emergency departments for several years, focusing on ambulatory expansion as a core element of its long-term growth strategy. In September, chief financial officer Mike Marks said HCA has an average of more than 14 outpatient facilities for every hospital and the goal is to increase that to 20 per hospital by 2030, Becker’s Hospital Review reported, noting that HCA started 2026 with about 2,700 outpatient sites.
Private equity firms kicked off 2026 by acquiring at least 21 outpatient medical practices in January alone, according to PESP. Most of those were specialty practices ranging from eye care and dermatology to pain management, pediatrics, primary care, and radiology.
Bain Capital, PESP noted, is the largest owner of Surgery Partners, a publicly traded company that operates more than 200 surgical facilities. As of April, Bain had a 38% stake in the company.
PESP reported that in a March filing with the Securities and Exchange Commission, Surgical Partners stated, “Although we are no longer a ‘controlled company’ …, affiliates of Bain Capital continue to be able to significantly influence our decisions.”
Dr. Derek Angus, a senior editor at JAMA, noted in an article accompanying a podcast interview with Dr. Sneha Kannan, assistant professor of critical care medicine at the University of Pittsburgh, that oversight of PE acquisition in healthcare “is fragmented and evolving.”
“In response to the rise in PE acquisitions, some states have begun introducing laws to directly limit owners’ influence on staffing, billing, and clinical practices, but there is no federal equivalent,” Dr. Angus wrote.
According to PESP, 11 state legislatures have passed legislation that increased oversight of healthcare deals, including those involving PE.
The lack of similar legislation at the federal level is almost certain to change. PBMs managed to obscure their business practices for years, but with enough prodding, Congress eventually initiated investigations.
Even though federal PBM legislation still has not been passed, PBMs have begun to self-regulate. We could see a similar pattern with PE.
Health Care Rounds #224: Sundar Subramanian, CEO, Zyter
Health care AI has a trust problem. Clinicians were overriding a high-performing AI tool 84% of the time, until one framework brought that number down to 1.6%. Sundar Subramanian, CEO of Zyter, joins John to explore why AI adoption stalls even when the technology works, how explainability and confidence scoring are the two levers that actually build clinician trust, and why redesigning care processes from the ground up produces outcomes that task automation never will. Find this episode on Spotify, Apple, YouTube, or wherever you get your podcasts.
What else you need to know
Bayer’s Sunharbo (asundexian) is approved for secondary stroke prevention, potentially marking one of the most impactful advancements in stroke prevention in decades. Specifically, Sunharbo, a first-in-class Factor XIa inhibitor, is indicated to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack in combination with antiplatelet therapy. Sunharbo is not approved for stroke prevention in patients with atrial fibrillation, the FDA stated in the approval notice.
Bayer noted in a news release that Sunharbo represents a new approach to lowering the risk of ischemic stroke. It’s the first drug approved in the U.S. to target Factor XIa, a plasma enzyme involved in the blood coagulation cascade. Inhibiting Factor XIa reduces amplification of the generation of thrombin, an enzyme involved in blood clotting. According to Bayer, inhibiting Factor XIa targets the more pathological form of clotting, thrombosis, with less impact on hemostatis, the normal clotting response.
In the Phase III trial supporting Sunharbo’s approval, the drug significantly reduced ischemic stroke by 26% compared with placebo. It also significantly reduced the risk of all strokes, both ischemic and hemorrhagic, compared with placebo. Of note, the overall rate of major bleeding was similar for Sunharbo and placebo.
According to the Centers for Disease Control and Prevention, more than 795,000 people per year in the U.S. experience a stroke, and nearly a quarter of those — about 185,000 — are people who have already had a stroke. About 87% of all strokes are ischemic, in which blood flow to the brain is blocked, and approximately 75% to 80% of ischemic strokes are non-cardioembolic.
Bayer anticipates that Sunharbo will begin shipping this month. A 30-day supply of Sunharbo will have a list price of $748.50, Biopharma Dive reported, citing a Bayer spokesperson.
The FDA approved Rybrevant Faspro (amivabtanab and hyaluronidase-lpuj) for treating adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed while on or after platinum-based chemotherapy and immunotherapy. Granted on an accelerated basis, the approval is the first in a decade for this patient population. It’s also the first approval of a dual-targeted therapy in this setting, targeting two key proteins: epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), Johnson & Johnson said in a press release.
Rybrevant Faspro is a subcutaneous formulation of Rybrevant and is marketed by J&J subsidiary Janssen Biotech. It was initially approved in December 2025 as a treatment for EGFR-mutated non-small cell lung cancer. The FDA noted in the recent approval announcement that Rybrevant Faspro is not approved for patients with oropharyngeal squamous cell carcinoma associated with human papillomavirus.
Finnish company Oura agreed to acquire Counsel Health, a primary care company that combines AI medical with in-house physicians to provide guidance and care. Oura, whose U.S. headquarters are in San Francisco, makes the Oura Ring, a wearable that measures and monitors physiological signals and biometrics. Under the terms of the definitive agreement, Oura will pay $625 million in cash to acquire Boston-based Counsel Health. If customary closing conditions are met, the companies anticipate finalizing the transaction by year-end.
Oura established a partnership with Counsel Health earlier this year to give its members access to Counsel Health’s chat capabilities and telehealth services within the Oura app. By bringing Counsel Health into Oura’s ecosystem, Oura shifts “from helping members understand their health to enabling them to act on it,” Oura said in a blog post. Once the acquisition has been completed, the companies plan to expand their collaboration within the areas of preventive care, acute care, and specialty and chronic care.
St. Luke’s Hospital signed a letter of intent to join St. Louis-based BJC Health. St. Luke’s is an independent nonprofit healthcare system with a 493-bed acute care hospital in Chesterfield, Mo., and 30 locations throughout the greater St. Louis area. BJC Health was established in 2024 when BJC Healthcare merged with Saint Luke’s Health System. With a network of 27 hospitals and hundreds of clinics and service organizations, BJC Health operates as BJC Healthcare in the St. Louis area (BJC East Region) and as Saint Luke’s in the Kansas City area (BJC West Region), according to the announcement. (St. Luke’s posted additional information, including FAQs, here.)
The University of Texas MD Anderson Cancer Center is investing $3.4 billion to expand facilities on its main campus in Houston. The funds will go toward two new buildings called Inspiration Tower and Prism. With 25 floors, the 1.4 million-square-foot Inspiration Tower will be the nation’s largest cancer-focused clinical facility, UT MD Anderson said in a news release. The 292,000-square foot Prism facility will be a next-generation hub for radiation oncology and diagnostic imaging, serving as many as 150,000 patients per year. Prism is expected to open in 2030 and Inspiration Tower in 2032.
What we’re reading
What private practices, hospitals and investors should know about the M&A market in cardiology. Cardiovascular Business, 10.13.26
Primary care is still underpaid and federal policy could make access worse. Medical Economics, 11.10.26
The CJR-X reckoning coming for 2,217 hospitals. Becker’s Hospital Review, 11.10.26
Subscribe to Our Take
Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.

